Provided is a bilirubin derivative-based ultrasound contrast agent for diagnosis and treatment. The fine particles including the bilirubin derivative are sensitive to reactive oxygen species (ROS), bind with hydrophobic drugs, and can effectively chelate metals such as iron oxide nanoparticles. Therefore, the fine particle of the present invention can be used as an ultrasound contrast agent for diagnosis, as a magnetic resonance imaging contrast agent, or as a carrier for hydrophobic drugs or platinum-based drugs.

Provided is a bilirubin derivative-based ultrasound contrast agent for diagnosis and treatment. The fine particles including the bilirubin derivative are sensitive to reactive oxygen species (ROS), bind with hydrophobic drugs, and can effectively chelate metals such as iron oxide nanoparticles. Therefore, the fine particle of the present invention can be used as an ultrasound contrast agent for diagnosis, as a magnetic resonance imaging contrast agent, or as a carrier for hydrophobic drugs or platinum-based drugs.

The present disclosure is directed to compounds, compositions, formulations and methods of use thereof in the treatment and prevention of ULK mediated diseases, including cancer.

The present disclosure is directed to compounds, compositions, formulations and methods of use thereof in the treatment and prevention of ULK mediated diseases, including cancer.

Disclosed are lipid compounds comprising imidazole heads and lipidoid nanoparticles (LNPs) comprising the lipidoid compounds disclosed herein for efficient nucleic acid delivery to T cells.

Disclosed are lipid compounds comprising imidazole heads and lipidoid nanoparticles (LNPs) comprising the lipidoid compounds disclosed herein for efficient nucleic acid delivery to T cells.

A platinum(II) complex of formula (I), ##STR00001## or a pharmaceutically acceptable solvate or tautomer thereof, wherein R.sup.1 and R.sup.2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; or wherein R.sup.1 and R.sup.2 together form a five-, six-, or seven-membered ring with the nitrogen atoms to which they are attached; and X is a nitrate anion, a hexafluorophosphate anion, a hexafluoroantimonate anion, a trifluoromethanesulfonate anion, a tetrafluoroborate anion, a perchlorate anion, or a halide anion. A pharmaceutical composition containing the platinum(II) complex of formula (I), and a method of treating cancer are also disclosed.

A platinum(II) complex of formula (I), ##STR00001## or a pharmaceutically acceptable solvate or tautomer thereof, wherein R.sup.1 and R.sup.2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; or wherein R.sup.1 and R.sup.2 together form a five-, six-, or seven-membered ring with the nitrogen atoms to which they are attached; and X is a nitrate anion, a hexafluorophosphate anion, a hexafluoroantimonate anion, a trifluoromethanesulfonate anion, a tetrafluoroborate anion, a perchlorate anion, or a halide anion. A pharmaceutical composition containing the platinum(II) complex of formula (I), and a method of treating cancer are also disclosed.

A compound represented by Formula 1 according to the present disclosure, when used in combination with an anticancer drug, may significantly improve the anticancer effect of the anticancer drug, and may induce the same anticancer effect even when the anticancer drug is used in a significantly smaller amount than the conventionally used amount, thereby reducing the side effects caused by administration of the anticancer drug. Furthermore, the compound represented by Formula 1 makes it possible to effectively prevent, alleviate or treat either anticancer-resistant cancer or cancer which recurs or metastasizes after anticancer drug treatment.

A compound represented by Formula 1 according to the present disclosure, when used in combination with an anticancer drug, may significantly improve the anticancer effect of the anticancer drug, and may induce the same anticancer effect even when the anticancer drug is used in a significantly smaller amount than the conventionally used amount, thereby reducing the side effects caused by administration of the anticancer drug. Furthermore, the compound represented by Formula 1 makes it possible to effectively prevent, alleviate or treat either anticancer-resistant cancer or cancer which recurs or metastasizes after anticancer drug treatment.